Digital Biomarkers

Leading the Technology

Digital biomarkers provide real-time data on patients’ physiology and disease progression to help researchers better understand treatment efficacy.

Leading the way in digital biomarkers technology, Clinical ink offers the best-in-class analytics platform to capture, collect, and interpret real-time data powering the evaluation and development of new treatments.

Our scientists, architects, data engineers, data scientists, and software engineers are advancing digital biomarkers technology.

Play Video

The Analysis Platform for Digital Biomarkers

Digital biomarkers for patient engagement

Measure Patient Response

  • Use any digital device to measure a patient’s biological response in real-time
  • Improve patient engagement and compliance
  • Visualize data in dashboards to monitor patient adherence and data quality
  • Build machine learning solutions to improve patient-centric insights into behavior and compliance
  • Perform root cause analysis to understand patient behavior in bring-your-own-device (BYOD) studies

Better Data. Better Decisions.

  • Validate measurements derived from sensors, algorithms, and clinical data in real-time
  • Fuse data sources from multiple sensors into a common reference frame
  • Ingest data into enterprise data lake solutions for expedited analysis
  • Conduct real-time quality control checks on incoming data sources
Digital biomarkers in clinical trials
Technology for patient retention in clinical trials

Develop Disease-Specific Digital Biomarkers

  • Evaluate sensor data streams to identify optimal solutions for capturing disease-relevant signals
  • Engineer features using time- and frequency-dependent signal processing routines and algorithms
  • Construct multivariate modeling methods to evaluate mixed effects in complex study designs

Power Innovation and Growth

Sponsors and researchers incorporating Digital Health Technologies (DHTs)—sensors and wearables—into their clinical trials are driving growth and innovation by ensuring the highest standards of data collection, transmission, security, quality, and analysis for optimal digital biomarkers. The Clinical ink platform and scalable analytics technology are essential to implementing and reinforcing these data standards. Enable patient-centric research via mobile assessments engineered by experienced clinical, software, data, and user experience experts.

Discover novel digital assessments being developed to validate digital biomarkers in PD and how they can be applied in clinical trials.

Frequently Asked Questions

Digital biomarkers are objective, quantifiable physiological and behavioral data that are collected and measured by digital devices such as smartphones, wearables, or sensors. They can provide insights into patients' health status, treatment response, and disease progression, enabling more personalized and timely therapeutic decisions.

Digital biomarkers offer several key benefits to clinical trial design and processes:


  • Real-Time Monitoring: Allows continuous tracking of patients' health, providing timely insights and enabling adaptive interventions.
  • Enhanced Data Quality: Objective and high-quality data minimizes human error and supports more robust analyses.
  • Patient-Centric Approach: Enables remote monitoring and participation, making trials more accessible and comfortable for patients.
  • Cost-Effective Solutions: Often more economical than traditional methods, facilitating broader and more diverse trials.
  • Support for Decentralized Trials: Digital biomarkers align with modern decentralized and trial approaches, promoting flexibility and innovation in trial design.

The Clinical ink platform supports a wide variety of digital biomarkers, including physiological metrics like heart rate, behavioral indicators like activity levels, patient-reported outcomes, and specialized health indicators. The flexibility of the platform ensures the collection of relevant and meaningful data for diverse clinical research solutions.

Digital biomarkers in clinical trials are data collected from digital devices. They are objective, measurable, and provide continuous, real-time information about a patient's health. These characteristics allow researchers to accurately track changes over time. Digital biomarkers are often non-intrusive, making them convenient for patients.
Unlike traditional endpoints, which are often measured during specific clinic visits, digital biomarkers in clinical trials provide continuous, real-time data. This continuous monitoring offers a more comprehensive and detailed view of a patient's health and behavior.
Yes, digital biomarkers in clinical trials can enhance patient recruitment and retention. They make participation more convenient for patients as they can be monitored remotely, reducing the need for frequent clinic visits. This convenience often attracts more participants to the trials.
Scroll to Top

Download the Digital Biomarkers White Paper

Progress in a New Era: Digital Biomarkers as Endpoints in Parkinson’s Disease
Discover novel digital assessments being developed to validate digital biomarkers in PD and how they can be applied in clinical trials.

Contact Clinical ink

Request more information, submit questions, set up a demonstration, and more.